Euploidy rates between cycles triggered with gonadotropin-releasing hormone agonist and human chorionic gonadotropin
Blastocyst euploidy rates are similar in in vitro fertilization cycles triggered with either gonadotropin-re- leasing hormone agonist or human chorionic gonadotropin.
Volume 112, Issue 2, Pages 258–265
Jeffrey Thorne, M.D., Alexandra Loza, D.O., Leah Kaye, M.D., John Nulsen, M.D., Claudio Benadiva, M.D., Daniel Grow, M.D., Lawrence Engmann, M.D.
To evaluate differences in euploidy rates between IVF cycles triggered with either GnRH agonist (GnRHa) or hCG.
Retrospective cohort study.
University-affiliated fertility center.
A total of 366 patients performing 539 IVF cycles utilizing preimplantation genetic testing for aneuploidy (PGT-A).
Gonadotropin-releasing hormone agonist or hCG trigger of oocyte maturation during IVF cycles.
Main Outcome Measure(s)
Rate of euploid embryos.
Patients in the GnRHa trigger arm were younger, with a lower body mass index and higher antimüllerian hormone level, and they had a higher number of oocytes retrieved and embryos biopsied. Euploid rate per embryo biopsied was higher after GnRHa trigger than after hCG trigger (37.8% ± 2.1% vs. 30.3% ± 1.8%), but multivariate regression analysis controlling for potential confounding factors did not show any differences between the two groups. Moreover, the euploid rate per oocyte retrieved was not significantly different overall (GnRHa vs. hCG: 33.9% ± 2.2% vs. 28.0% ± 1.9%). The anticipated decline in the rate of euploid embryos per oocyte retrieved went from 15.8% ± 1.2% for age <35 years to 4.3% ± 0.9% for patients aged ≥41 years. There were no significant differences between the two groups after stratifying by age and controlling for PGT-A testing modality.
Both GnRHa and hCG trigger result in comparable euploid rates. Trigger with GnRHa should therefore be considered a valid option for trigger modality in freeze-all PGT-A cycles, in view of its demonstrated effectiveness and known safety enhancement.